<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR16">
 <label>16.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Lamarque</surname>
    <given-names>M</given-names>
   </name>
   <name>
    <surname>Bossard</surname>
    <given-names>C</given-names>
   </name>
   <name>
    <surname>Contejean</surname>
    <given-names>A</given-names>
   </name>
   <name>
    <surname>Brice</surname>
    <given-names>P</given-names>
   </name>
   <name>
    <surname>Parrens</surname>
    <given-names>M</given-names>
   </name>
   <name>
    <surname>Le Gouill</surname>
    <given-names>S</given-names>
   </name>
   <name>
    <surname>Bri√®re</surname>
    <given-names>J</given-names>
   </name>
   <name>
    <surname>Bouabdallah</surname>
    <given-names>R</given-names>
   </name>
   <name>
    <surname>Canioni</surname>
    <given-names>D</given-names>
   </name>
   <name>
    <surname>Tilly</surname>
    <given-names>H</given-names>
   </name>
   <name>
    <surname>Bouchindhomme</surname>
    <given-names>B</given-names>
   </name>
   <name>
    <surname>Bachy</surname>
    <given-names>E</given-names>
   </name>
   <name>
    <surname>Delarue</surname>
    <given-names>R</given-names>
   </name>
   <name>
    <surname>Haioun</surname>
    <given-names>C</given-names>
   </name>
  </person-group>
  <article-title>Gaulard P (2016) Brentuximab vedotin in refractory or relapsed peripheral T-cell lymphomas: the French named patient program experience in 56 patients</article-title>
  <source>Haematologica</source>
  <year>2016</year>
  <volume>101</volume>
  <fpage>e103</fpage>
  <lpage>e106</lpage>
  <pub-id pub-id-type="doi">10.3324/haematol.2015.135400</pub-id>
  <pub-id pub-id-type="pmid">26703966</pub-id>
 </element-citation>
</ref>
